Biofrontera (BFRI) Competitors $1.10 -0.03 (-2.65%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$1.12 +0.01 (+1.36%) As of 10/24/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. OKUR, LVTX, XLO, ELUT, RVPH, BTAI, NEUP, MURA, BCAB, and ITRMShould you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include OnKure Therapeutics (OKUR), LAVA Therapeutics (LVTX), Xilio Therapeutics (XLO), Elutia (ELUT), Reviva Pharmaceuticals (RVPH), BioXcel Therapeutics (BTAI), Neuphoria Therapeutics (NEUP), Mural Oncology (MURA), BioAtla (BCAB), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Biofrontera vs. Its Competitors OnKure Therapeutics LAVA Therapeutics Xilio Therapeutics Elutia Reviva Pharmaceuticals BioXcel Therapeutics Neuphoria Therapeutics Mural Oncology BioAtla Iterum Therapeutics Biofrontera (NASDAQ:BFRI) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Does the media refer more to BFRI or OKUR? In the previous week, Biofrontera had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Biofrontera and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.91 beat Biofrontera's score of 1.29 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biofrontera Positive OnKure Therapeutics Very Positive Do analysts recommend BFRI or OKUR? Biofrontera presently has a consensus price target of $2.75, suggesting a potential upside of 150.00%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 873.90%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Biofrontera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has preferable earnings & valuation, BFRI or OKUR? Biofrontera has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$37.32M0.30-$17.76M-$2.26-0.49OnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.69 Is BFRI or OKUR more profitable? OnKure Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -42.34%. OnKure Therapeutics' return on equity of -60.52% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-42.34% -1,104.09% -82.28% OnKure Therapeutics N/A -60.52%-55.43% Which has more volatility and risk, BFRI or OKUR? Biofrontera has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Do insiders & institutionals have more ownership in BFRI or OKUR? 10.1% of Biofrontera shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryOnKure Therapeutics beats Biofrontera on 9 of the 16 factors compared between the two stocks. Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition Export to ExcelMetricBiofronteraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.15M$3.46B$6.22B$10.81BDividend YieldN/A2.28%5.72%4.81%P/E Ratio-0.4928.5131.5430.95Price / Sales0.30497.40595.06133.74Price / CashN/A46.9537.2561.86Price / Book1.9310.4012.056.61Net Income-$17.76M-$52.83M$3.34B$277.10M7 Day Performance14.58%2.10%1.93%2.57%1 Month Performance14.57%12.33%7.77%3.79%1 Year Performance21.20%14.14%56.40%33.01% Biofrontera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera2.4387 of 5 stars$1.10-2.7%$2.75+150.0%+13.4%$11.15M$37.32M-0.4970News CoverageHigh Trading VolumeOKUROnKure Therapeutics3.9435 of 5 stars$3.00+2.4%$32.33+977.8%-80.7%$39.64MN/A-0.63N/APositive NewsAnalyst ForecastLVTXLAVA Therapeutics1.6707 of 5 stars$1.47-1.3%$2.69+82.7%-19.5%$39.19M$11.98M-1.4060Analyst ForecastHigh Trading VolumeXLOXilio Therapeutics1.9996 of 5 stars$0.76+0.2%$3.00+297.1%-14.7%$39.06M$6.34M-0.9970Analyst ForecastELUTElutia2.9191 of 5 stars$0.90-0.2%$7.00+681.3%-72.1%$38.05M$24.38M-0.85180News CoverageAnalyst ForecastGap DownRVPHReviva Pharmaceuticals3.6725 of 5 stars$0.52-2.9%$4.86+834.1%-40.8%$37.12MN/A-0.805Positive NewsAnalyst ForecastOptions VolumeGap UpBTAIBioXcel Therapeutics3.9718 of 5 stars$2.20-3.9%$39.75+1,706.8%-75.7%$36.66M$2.27M-0.1790News CoverageAnalyst ForecastNEUPNeuphoria Therapeutics3.33 of 5 stars$4.85-68.5%$28.00+477.3%N/A$36.31M$15.65M0.00N/ANews CoverageAnalyst ForecastInsider TradeGap UpHigh Trading VolumeMURAMural Oncology2.8165 of 5 stars$2.09flat$12.00+474.2%-40.1%$36.21MN/A-0.24119News CoverageBCABBioAtla0.798 of 5 stars$0.69+12.4%N/A-60.2%$36.06M$11M-0.6360News CoverageITRMIterum Therapeutics2.8294 of 5 stars$0.73-2.1%$9.00+1,126.3%-40.6%$36.04MN/A-0.8610Positive NewsAnalyst Forecast Related Companies and Tools Related Companies OKUR Competitors LVTX Competitors XLO Competitors ELUT Competitors RVPH Competitors BTAI Competitors NEUP Competitors MURA Competitors BCAB Competitors ITRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
